• share
• favorite_border

鈥� Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors 鈥� One patient experienced a complete response, and one patient had a partial response 鈥� This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less 鈥� AIC100 is a CAR T cell therapy that targets the ICAM-1 protein on tumor cells

• share
• favorite_border

鈥� Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer

• share
• favorite_border

鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

• share
• favorite_border

路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

• share
• favorite_border

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.

• share
• favorite_border

鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

• share
• favorite_border

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

• share
• favorite_border

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

• share
• favorite_border

Ludwig Cancer Research is proud to support eight early-career scientists presenting their research at the conference this year through the AACR Scholar-in-Training Awards (SITA) program, contributing to the cost of their travel and attendance at the conference.

• share
• favorite_border

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system鈥檚 ability to kill cancer cells 鈥� but these drugs do not produce a lasting response in most patients with this cancer type.

• share
• favorite_border

Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held online and in person in Chicago, from April 25 to April 30.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer.

• share
• favorite_border

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

• share
• favorite_border

EXPLORER total body PET scanner is creating a new way to visualize the protective barrier to the brain to reveal impacts from cancer and other diseases.

• share
• favorite_border

Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at the American Association for Cancer Research (AACR) Annual Meeting 2025.

• share
• favorite_border

Michael J. Schell, Ph.D., interim chief in the Quantitative Science Division at Moffitt Cancer Center, has been elected a Fellow of the American Statistical Association (ASA), the world鈥檚 largest community of statisticians and data scientists. This prestigious honor recognizes his exceptional contributions to statistical sciences and his commitment to advancing the field.

• share
• favorite_border

Researchers from Moffitt Cancer Center will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will take place April 25-30 in Chicago. Follow us @MoffittNews for updates.

• share
• favorite_border

Yale Cancer Center (YCC) experts will present at the 2025 American Association of Cancer Research (AACR) Annual Meeting, which kicks off this Friday in Chicago at the McCormick Place Convention Center. As one of the largest global gatherings of cancer experts, the meeting will highlight new cancer treatments and practice-changing clinical trials from around the world.